Gut Microbiota, SCFAs and Glucolipid Metabolism in Pregnant Women With Abnormal Fetal Size and Their Newborns
Study on the Relationship of Gut Microbiota and Changes of SCFAs With Glucolipid Metabolism in Pregnant Women With Abnormal Fetal Size and Their Newborns
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ying Hua
- Phone Number: +8613676403165 +8613676403165
- Email: wzfeyhy1015@126.com
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325027
- Recruiting
- department of obstetrics of Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- ying hua, Doctor
- Phone Number: 13676403165
- Email: wzfeyhy1015@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Singleton pregnancy
- Term pregnancy with the gestational age of 37-40 weeks
Exclusion Criteria:
- Maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy)
- Delivery before 37 weeks or after 40 weeks
- Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
normal pregnancy
pregnancy with a normal fetal size
|
test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
|
|
fetal growth restriction
fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
|
test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
|
|
fetal macrosomia
fetal birth weight ≥ 4000g
|
test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut Microbiota and SCFAs in mothers and their newborns
Time Frame: Stool samples from pregnant women with 37-40 gestational week and newborns within 3 days after birth
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples
|
Stool samples from pregnant women with 37-40 gestational week and newborns within 3 days after birth
|
|
glucolipid metabolism and insulin sensitivity in pregnant women
Time Frame: Blood samples from pregnant women with 37-40 gestational week
|
glucolipid metabolism and insulin sensitivity in pregnant women with normal and abnormal fetal size
|
Blood samples from pregnant women with 37-40 gestational week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Body Weight
- Fetal Diseases
- Pregnancy Complications
- Growth Disorders
- Diabetes, Gestational
- Pregnancy in Diabetics
- Birth Weight
- Fetal Growth Retardation
- Fetal Macrosomia
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Insulin
Other Study ID Numbers
Other Study ID Numbers
- SAHoWMU-CR2020-07-209
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.